Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea
MENLO PARK, Calif., July 27, 2017 – BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that a panel of prominent dermatologists will discuss BPX-01, a unique topical hydrophilic gel formulation of minocycline at the 2017 AAD Summer Meeting tomorrow. BPX-01 is an investigational drug for the treatment of acne and rosacea.
The discussion will take place during a three hour-long “Acne and Rosacea Session” at 1 p.m. Eastern, at the New York Hilton Midtown. Dermatologists involved in the panel include Dr. James Del Rosso, a board-certified dermatologist and researcher who is a member of the BioPharmX Dermatology Medical Advisory Board; Dr. Andrew Alexis, chairman of the Department of Dermatology at Mount Sinai St. Luke’s and Mount Sinai West in New York City, and Dr. Linda Stein Gold, director of Dermatology Clinical Research at Henry Ford Health System in Detroit.
Phase 2b data found BPX-01 reduced acne lesions by 59%, delivered at least a two-grade reduction to clear or almost clear in investigator global assessments for 25% of subjects and was generally well tolerated, without any serious drug-related adverse events, photosensitivity, staining or skin discoloration. A survey of study participants found 86% would use BPX-01 again and 79% said the drug was easy to use and apply.
“The dermatology community is excited about these promising clinical results,” said Hilary E. Baldwin, MD, Clinical Associate Professor, Rutgers Robert Wood Johnson Medical Center, Medical Director, Acne Treatment & Research Center and Co-Chair of BioPharmX Medical Advisory Board, “There has been little innovation in acne treatment for several decades. BPX-01 could lead to significant change in the standard of care.”
The company is currently conducting an open-label phase 2 feasibility study for rosacea and continues making progress toward the next phase in trials for acne vulgaris.
The American Academy of Dermatology calls acne the “most common skin condition in the United States,” affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
MENLO PARK, Calif., July 27, 2017 – BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that a panel of prominent dermatologists will discuss BPX-01, a unique topical hydrophilic gel formulation of minocycline at the 2017 AAD Summer Meeting tomorrow. BPX-01 is an investigational drug for the treatment of acne and rosacea.
The discussion will take place during a three hour-long “Acne and Rosacea Session” at 1 p.m. Eastern, at the New York Hilton Midtown. Dermatologists involved in the panel include Dr. James Del Rosso, a board-certified dermatologist and researcher who is a member of the BioPharmX Dermatology Medical Advisory Board; Dr. Andrew Alexis, chairman of the Department of Dermatology at Mount Sinai St. Luke’s and Mount Sinai West in New York City, and Dr. Linda Stein Gold, director of Dermatology Clinical Research at Henry Ford Health System in Detroit.
Phase 2b data found BPX-01 reduced acne lesions by 59%, delivered at least a two-grade reduction to clear or almost clear in investigator global assessments for 25% of subjects and was generally well tolerated, without any serious drug-related adverse events, photosensitivity, staining or skin discoloration. A survey of study participants found 86% would use BPX-01 again and 79% said the drug was easy to use and apply.
“The dermatology community is excited about these promising clinical results,” said Hilary E. Baldwin, MD, Clinical Associate Professor, Rutgers Robert Wood Johnson Medical Center, Medical Director, Acne Treatment & Research Center and Co-Chair of BioPharmX Medical Advisory Board, “There has been little innovation in acne treatment for several decades. BPX-01 could lead to significant change in the standard of care.”
The company is currently conducting an open-label phase 2 feasibility study for rosacea and continues making progress toward the next phase in trials for acne vulgaris.
The American Academy of Dermatology calls acne the “most common skin condition in the United States,” affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
